系列18F-氟脱氧葡萄糖正电子发射断层显像在判定心脏结节病患者免疫抑制治疗疗效与临床结局中的作用
本研究纳入113例新诊断且有活动性心肌炎症的心脏结节病患者,在免疫抑制治疗后6至12个月复查FDG-PET、铷-82 PET及超声心动图。中位随访46个月后28例(25%)达到复合终点,治疗前后灌注缺损范围均大于10%者不良事件风险最高,灌注缺损范围是主要预测因素。
要点
- 免疫抑制治疗后SUVmax从4.5降至2.7,94例(83%)出现系列下降,42例(37%)达完全缓解。
- 治疗后灌注缺损范围可预测不良事件(HR 1.03,95%CI 1.01-1.05,p=0.035)。
- 治疗前或治疗后灌注缺损范围大于10%者不良事件风险最高。
核心结论
- 在活动性心脏结节病队列中,治疗引起心肌炎症减轻后,灌注缺损范围是不良事件的主要预测因素。
研究设计与样本
- 新诊断且存在活动性心肌炎症(SUVmax≥2.5)的心脏结节病患者接受免疫抑制治疗,6至12个月后复查FDG-PET、铷-82 PET及超声心动图。
- 研究共纳入113例患者,男性占66%,年龄55±11岁,左心室射血分数54±13%。
- 主要终点为全因死亡、严重室性心律失常和心力衰竭住院的复合终点,事件数据自第二次FDG-PET之日起记录。
主要发现
- SUVmax从4.5(四分位距3.3-7.1)降至2.7(2.2-3.6),94例(83%)出现SUVmax系列下降,42例(37%)达完全缓解(SUVmax<2.5)。
- 中位随访46(25-57)个月后,28例(25%)达到终点,包括8例死亡、17例室性心律失常和3例心力衰竭住院。
- 灌注缺损范围可显著预测治疗后结局(HR 1.03,95%CI 1.01-1.05,p=0.035),校正左心室射血分数和SUVmean变化后仍显著。
- 治疗前或治疗后灌注缺损范围大于10%者不良事件风险最高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial inflammation and perfusion defects detected by 18F-fludeoxyglucose (FDG) and Rubidium-82 positron emission tomography (PET) may be associated with ventricular arrhythmias (VAs) in cardiac sarcoidosis (CS). The role of serial quantitative PET in determining the effect of treatment on myocardial inflammation and clinical outcomes is yet to be defined. METHODS: Newly diagnosed CS patients with active myocardial inflammation (maximum standardised uptake value (SUVmax) ≥ 2.5) were treated with immunosuppression, then underwent repeat FDG-PET, Rubidium-82, and echocardiographic imaging 6-12 months later. Serial changes in SUVmax, SUVmean, inflammatory extent, perfusion defect (PD) extent, metabolism/perfusion mismatch extent, global cardiac metabolic activity, and left ventricular ejection fraction (LVEF) were assessed. The primary endpoint was a composite of all-cause mortality, serious VA and heart-failure (HF) hospitalisation. Event data were recorded from the date of the second FDG-PET. RESULTS: The study population consisted of 113 patients (66% male, age: 55 ± 11 years, LVEF: 54 ± 13%). SUVmax reduced from 4.5 (interquartile range: 3.3-7.1) to 2.7 (2.2-3.6). Overall, 94 (83%) patients saw serial reduction in SUVmax, with 42 (37%) demonstrating complete response (SUVmax <2.5). Following a median of 46 (25-57) months, 28 (25%) patients reached the endpoint (8 deaths, 17 VAs, and 3 HF hospitalisations). PD extent (Hazard ratio 1.03, 95% confidence interval: 1.01-1.05; p = 0.035) was a significant predictor of outcome following treatment, even after accounting for LVEF and change in SUVmean. The risk of adverse events was the greatest in those with a pre-treatment or post-treatment PD extent of >10%. CONCLUSION: In our cohort with active CS, following a treatment-induced reduction in myocardial inflammation, PD extent was the main predictor of adverse events.
引用
- Okafor J, Khattar R, Kouranos V, et al. Role of serial 18F-fludeoxyglucose positron emission tomography in determining the therapeutic efficacy of immunosuppression and clinical outcome in patients with cardiac sarcoidosis. J Nucl Cardiol. 2024. PMID: 38479574. doi:10.1016/j.nuclcard.2024.101842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。